Artificial intelligence in the prediction of protein-ligand interactions: recent advances and future directions.

Journal: Briefings in bioinformatics
Published Date:

Abstract

New drug production, from target identification to marketing approval, takes over 12 years and can cost around $2.6 billion. Furthermore, the COVID-19 pandemic has unveiled the urgent need for more powerful computational methods for drug discovery. Here, we review the computational approaches to predicting protein-ligand interactions in the context of drug discovery, focusing on methods using artificial intelligence (AI). We begin with a brief introduction to proteins (targets), ligands (e.g. drugs) and their interactions for nonexperts. Next, we review databases that are commonly used in the domain of protein-ligand interactions. Finally, we survey and analyze the machine learning (ML) approaches implemented to predict protein-ligand binding sites, ligand-binding affinity and binding pose (conformation) including both classical ML algorithms and recent deep learning methods. After exploring the correlation between these three aspects of protein-ligand interaction, it has been proposed that they should be studied in unison. We anticipate that our review will aid exploration and development of more accurate ML-based prediction strategies for studying protein-ligand interactions.

Authors

  • Ashwin Dhakal
    Department of Electrical Engineering and Computer Science, University of Missouri, Columbia, MO 65211, USA.
  • Cole McKay
    Department of Biochemistry, University of Missouri, Columbia, MO, 65211, USA.
  • John J Tanner
    Departments of Biochemistry and Chemistry, University of Missouri, Columbia, MO, 65211-2060, USA.
  • Jianlin Cheng
    Department of Electrical Engineering and Computer Science, University of Missouri, Columbia, MO, USA.